Explore 3 Stock Ideas & Industry Insights Download Free Report

Avenue Therapeutics Inc

Company price
0.3 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
457
Market Cap
2.11M

Momentum Score

…

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.30
Low
0.30
High
52 Week Price Range
0.15
Low
0.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avenue Therapeutics is a specialty pharmaceutical company developing an intravenous tramadol formulation for management of moderate-to-severe acute pain in adults. Long-term growth drivers include achieving regulatory approval and commercial launch of its lead product candidate and potential uptake in surgical and emergency settings seeking IV analgesics with lower abuse profiles than stronger opioids. The company may appeal to investors interested in a focused pipeline targeting an addressable acute-pain market if clinical and regulatory milestones are achieved.

Key investment risks include regulatory and clinical outcome uncertainty, limited cash and the need for additional financing, competition from established analgesics and generics, and commercialization and reimbursement challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.30
Dividend Yield
-
Revenue TTM
1.40M
Revenue Per Share
0.45
Gross Profit TTM
1.40M
Debt / Equity
-
ROE
-159.82%
Net Debt
-2.85M
ROCE
-179.37%
Diluted EPS TTM
-0.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.95M -11.70M -10.49M -3.60M -3.73M
Minority interest 0.04M 0.04M 0.11M 0.05M -
Net income -2.91M -11.65M -10.38M 2.05M -3.72M
Selling general administrative 3.65M 4.64M 4.18M 5.34M 2.48M
Selling and marketing expenses - - 4.17M - -
Gross profit 1.40M - - - -
Ebit - - -10.49M -8.04M -3.74M
Ebitda -3.29M -11.70M 4.05M -8.02M -3.74M
Depreciation and amortization - - 14.54M 0.02M 0.01M
Operating income -3.29M -11.28M -14.54M -8.04M -3.74M
Other operating expenses 4.69M 11.28M 14.54M 8.04M 3.74M
Interest expense - 0.00M 0.33M 1.16M 0.01M
Interest income 0.12M 0.18M 0.13M 0.02M 0.01M
Net interest income 0.12M 0.18M -0.21M -1.14M 0.01M
Income tax expense - - -0.11M -5.65M -0.01M
Total revenue 1.40M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 4.69M 11.28M 14.54M 8.04M 3.74M
Total other income expense net 0.34M -0.41M 4.05M 4.44M 0.01M
Net income from continuing ops -2.95M -11.70M -10.49M -3.60M -3.73M
Net income applicable to common shares - - - - -3.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.93M 2.67M 1.85M 6.84M 3.96M
Other current assets 0.08M 0.08M 0.07M 0.14M 0.11M
Total liab 1.10M 0.82M 1.20M 3.58M 0.51M
Total stockholder equity 1.83M 2.80M 1.58M 3.90M 3.45M
Other current liab 1.10M 0.66M 0.80M 2.61M 0.15M
Common stock - - 0.00M - 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -105.49M -102.58M -90.93M -80.55M -77.00M
Other assets 0.08M 0.08M 0.07M 0.00M -
Cash 2.85M 2.59M 1.78M 6.71M 3.76M
Total current liabilities 1.10M 0.82M 1.20M 3.58M 0.51M
Net debt -2.85M -2.59M -1.78M -6.71M -3.76M
Other stockholder equity 107.32M 105.38M 92.51M 84.46M 80.45M
Total current assets 2.85M 2.67M 1.85M 6.84M 3.96M
Net tangible assets - - - - 3.45M
Net receivables - - - - 0.09M
Inventory - - - - 0.11M
Accounts payable 0.09M 0.15M 0.40M 0.97M 0.36M
Accumulated other comprehensive income - - 0.00M - -
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -3.00M - 0.00M
Change to liabilities - - - 0.35M -0.38M
Total cashflows from investing activities - - -3.00M - -
Total cash from financing activities 2.09M 9.84M 7.53M 10.54M 4.38M
Change to operating activities - - - -0.03M -0.08M
Net income -2.91M -11.70M -10.38M -3.60M -3.73M
Change in cash 0.26M 0.81M -4.92M 2.94M 0.63M
Begin period cash flow 2.59M 1.78M 6.71M 3.76M 3.13M
End period cash flow 2.85M 2.59M 1.78M 6.71M 3.76M
Total cash from operating activities -1.83M -9.03M -9.45M -7.60M -3.75M
Issuance of capital stock 2.09M 1.62M 7.53M 12.01M 5.04M
Other cashflows from investing activities - - -3.00M - -
Change to account receivables - - - 0.09M -0.09M
Sale purchase of stock -0.00M - 1.23M -1.10M -
Other cashflows from financing activities 2.09M 8.21M 0.00M -0.36M -0.66M
Change to netincome - - - -4.45M 0.44M
Capital expenditures 0.00M 0.00M 3.00M 0.00M 0.00M
Change in working capital 0.30M 0.18M -0.29M 0.41M -0.46M
Stock based compensation 0.67M 1.24M 0.91M 0.65M 0.44M
Other non cash items 0.11M 1.25M 0.31M -5.05M 4.19M
Free cash flow -1.83M -9.03M -12.45M -7.60M -3.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ATXI
Avenue Therapeutics Inc
-
-%
0.30 - 17.99 1.50 1.03 -0.42
NVO
Novo Nordisk A/S
0.04
0.09%
38.91 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
5.97
1.15%
526.63 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
9.17
0.99%
932.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

781 652 4500

1

Name Title Year Born
Dr. Lindsay Allan Rosenwald Exec. Chairman 1955
Dr. Xiaoqin Lu M.D. Consultant 1975
Dr. Alexandra MacLean M.D. Chief Exec. Officer 1967
Mr. David Jin Interim CFO, COO & Corp. Sec. 1990
Dr. Scott A. Reines M.D., Ph.D. Interim Chief Medical Officer 1947
Srinivas Subramanian Exec. VP NA
Dr. Alexandra MacLean M.D. CEO & Director 1968
Mr. David Jin Interim CFO, COO & Corporate Secretary 1991
Dr. Lindsay Allan Rosenwald Executive Director 1955
Mr. Srinivas Subramanian Executive Vice President 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…